Analysts’ Top Healthcare Picks: JNCE, UTHR

By Jason Carr

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Jounce Therapeutics Inc (NASDAQ: JNCE) and United Therapeutics (NASDAQ: UTHR) with bullish sentiments.

Jounce Therapeutics Inc (NASDAQ: JNCE)

Cowen & Co. analyst Boris Peaker reiterated a Buy rating on Jounce Therapeutics Inc (NASDAQ: JNCE) today. The company’s shares opened today at $15.26.

Peaker observed:

“JNCE reiterated guidance for the JTX-2011 program which is expected to report.”

According to TipRanks.com, Peaker is a 4-star analyst with an average return of 5.2% and a 43.1% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Iovance Biotherapeutics Inc, and Corvus Pharmaceuticals Inc.

Currently, the analyst consensus on Jounce Therapeutics Inc is Moderate Buy and the average price target is $30, representing a 96.6% upside.

In a report issued on November 7, Robert W. Baird also reiterated a Buy rating on the stock with a $30 price target.
United Therapeutics (NASDAQ: UTHR)

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on United Therapeutics (NASDAQ: UTHR), with a price target of $213. The company’s shares opened today at $120.24, close to its 52-week low of $112.01.

According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 9.9% and a 43.1% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals Inc, Catabasis Pharmaceuticals, and Global Blood Therapeutics.

United Therapeutics has an analyst consensus of Hold, with a price target consensus of $143.40.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.